ChloraPrep™ - The Benefits

ChloraPrep™ provides rapid-acting, persistent, and broad-spectrum antiseptic activity for a range of minor and major medical procedures.

Proven formulation
The 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol formulation acts fast 1 ,2 on a broad spectrum of bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA) 2, and keeps fighting bacteria for at least 48 hours. 1, 3

Proven Device
The applicator's soft sponge, applied with a gentle back and forth motion, helps the solution penetrate the first five cell layers of the epidermis, helping to reduce skin-dwelling microorganisms that can cause bloodstream infections (BSIs) and surgical site infections (SSIs). The applicator design eliminates direct hand-to-patient contact, helping prevent cross contamination. 9

Together, the formulation and applicator provide a proven system that supports infection control guidelines to help reduce the incidence of BSIs and SSIs.

Comparison of Antimicrobial Agents
Active AgentsTraditional IodophorsAlcoholChlorhexidine
Broad Spectrum
Rapid Activity
Residual Activity
Activity in Blood/Organic Matter
Non/Minimal Absorption

ChloraPrep is superior compared to traditional iodophors

  • Rapid acting: The 70% isopropyl alcohol in ChloraPrep rapidly kills microorganisms versus free iodine, which requires two minutes to begin antimicrobial activity. 2, 4
  • Persistent: ChloraPrep maintains antimicrobial activity for at least 48 hours 1 ,3 compared to two hours for free iodine 4
  • Broad spectrum: ChloraPrep antimicrobial activity is effective against microorganisms including gram-positive and gram-negative bacteria, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci(VRE), Clostridium difficile, Acinetobacter, and most viruses and fungi. 2 ,4 ,5
  • Active in protein-rich biomaterials: Remains active in the presence of blood, serum, and other protein-rich biomaterials unlike traditional iodophors, which are neutralized. 2 ,4
  • Non/Minimal absorption.4

Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.

  1. Analyses comparing the antimicrobial activity and safety of current antiseptic agents: A review, Hibbard JS, J Infus Nurs 2005; 28: 194-207
  2. Current approaches for the prevention of surgical site infections Florman S, Nichols RL American Journal of Infectious Diseases 2007; 3: 51-61
  3. Comparison of ChloraPrep™ and Betadine® as preoperative skin preparation antiseptics, Garcia R, Hibbard JS, Mulberry G et al, Abstracts of the Infectious Disease Society of America 40th Annual Meeting 2002: Abs 418
  4. Skin antisepsis: past, present, and future, Crosby CT, Mares AK, J Vasc Access Devices 2001; Spring: 26-31
  5. Data on file, BD
  6. Microbial Ecology of Human Skin in Health and Disease, Fredericks DN, J Invest Dermatol Symp Proc 2001; 6: 167-9
  7. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin, Hendley JO, Ashe KM, Antimicrob Agents Chemother 1991; 35: 627-31
  8. Chlorhexidine: Expanding the armamentarium for infection control and prevention, Milstone AM, Passaretti CL, Perl TM, CID 2008; 46: 274-80
  9. Evaluation of donor arm disinfection techniques, McDonald CP, Lowe P, Roy A, Vox Sanguinis 2001; 80: 135-41
  10. The management and control of hospital acquired infection in acute NHS trusts in England, National Audit Office, February 2000
  11. The socioeconomic burden of hospital acquired infection, Plowman R, Graves N, Griffin M et al,
  12. The cost-effectiveness of 2% chlorhexidine gluconate in 70% isopropyl alcohol in prevention of central venous access device-related infections in patients admitted to ITU, York N, Hartley-Jones c, Hutchinson J et al, Poster presented at 37th Annual Infection Control Conference, UK, September
  13. Reducing blood-culture contamination rates by the use of a 2% chlorhexidine solution applicator in acute admission units, Madeo M, Barlow G, Hosp Infect 2008; 69: 307-9
  14. Efficacy of surgical preparation solutions in foot and ankle surgery, Ostrander RV, Botte MJ, Brage ME, J Bone Joint Surg Am 2005; 87: 980-5
  15. Prospective, randomised clinical trial to compare the efficacy of two 70% (v/v) isopropyl alcohol (IPA) solutions containing either 0.5% (w/v) or 2% (w/v) chlorhexidine gluconate (CHG) for skin antisepsis during coronary artery bypass grafting (CABG), Casey AL, Itrakjy AS, Harbun C et al, Poster presented at European Congress of Clinical Microbiology and Infection Diseases (ECCMID), Spain, April 2008


This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.